Tunlametinib
- Generic Name
- Tunlametinib
- Indication
适用含抗PD-1/PD-L1治疗失败的NRAS突变的晚期黑色素瘤、结直肠癌患者。
Study of HL-085 in NRAS Mutant Advanced Melanoma
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03973151
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT03781219
- Locations
- 🇨🇳
First Affiliated Hospital, Medicine School of Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Henan Province Oncology Hospital, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath